<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03586570</url>
  </required_header>
  <id_info>
    <org_study_id>ID-080-107</org_study_id>
    <nct_id>NCT03586570</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects</brief_title>
  <official_title>A Single-center, Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, and Pharmacokinetics After Multiple-dose Administration of 25 mg Aprocitentan in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Idorsia Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Biotech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Idorsia Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the tolerability, safety, and pharmacokinetics
      after multiple-dose administration of aprocitentan (25 mg) in healthy Japanese and Caucasian
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2018</start_date>
  <completion_date type="Actual">September 10, 2018</completion_date>
  <primary_completion_date type="Actual">September 10, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax during the first and last dosing interval</measure>
    <time_frame>From study treatment administration to 216 hours after last administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (tmax) during the first and last dosing interval</measure>
    <time_frame>From study treatment administration to 216 hours after last administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCÏ„ on the first and last day of study treatment intake</measure>
    <time_frame>From study treatment administration to 216 hours after last administration</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Aprocitentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprocitentan 25mg</intervention_name>
    <description>Oral tablets in strength of 25 mg</description>
    <arm_group_label>Aprocitentan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets matching aprocitentan tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be of Caucasian or Japanese ethnicity

          -  Signed informed consent in a language understandable to the subject prior to any
             study-mandated procedure

          -  Body mass index (BMI) of 18.0 to 28.0 kg/m2 (inclusive) at Screening

          -  Systolic blood pressure 100-145 mmHg, diastolic blood pressure 50-90 mmHg, and pulse
             rate 45-90 bpm (inclusive), measured on the same arm, after 5 min in the supine
             position at Screening

          -  A woman of childbearing potential is eligible only if the following applies:

        Negative serum pregnancy test at Screening,

        Negative urine pregnancy test on Day -1,

        Agreement to consistently and correctly use a reliable method of contraception from
        Screening up to at least 30 days after last study treatment administration

        Japanese subjects only

          -  Subjects must be of native Japanese descent (all parents/grandparents of Japanese
             descent).

          -  Subjects must not have been away from Japan for more than 10 years (at Screening
             visit).

          -  Subject's lifestyle should not have changed significantly since relocation from Japan

        Exclusion Criteria:

          -  Previous exposure to aprocitentan and/or macitentan.

          -  Known hypersensitivity to aprocitentan or treatments of the same class, or any of the
             excipients

          -  Pregnant or lactating women

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             full participation in the study or compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Idorsia Pharmaceuticals Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>October 16, 2018</last_update_submitted>
  <last_update_submitted_qc>October 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

